Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center

Table 3

Adverse events (n = 38).

Adverse events	Grades 1-2	Grades 3-4	Any grade
All	38 (100%)	25 (67.8%)	38 (100%)
Hand-foot skin reactions	8 (21.1%)	2 (5.2%)	8 (26.3%)
Hypertension	10 (26.3%)	3 (7.9%)	13 (34.2%)
Diarrhea	7 (18.4%)	1 (2.6%)	8 (21.1%)
Rash	6 (15.8%)	0	6 (15.8%)
RCCEP	8 (21.1%)	1 (2.6%)	9 (23.7%)
Nausea and/or vomiting	30 (78.9%)	2 (5.2%)	32 (84.2%)
Fatigue	16 (42.1%)	1 (2.6%)	17 (44.7%)
Decreased appetite	33 (86.8%)	2 (5.2%)	35 (92.1%)
Fever	26 (68.4%)	4 (10.5%)	30 (78.9%)
Abdominal pain	27 (71.1%)	5 (13.2%)	32 (84.2%)
Increased ALT/AST	30 (78.9%)	5 (13.2%)	35 (92.1%)
Leukopenia	6 (15.8%)	1 (2.6%)	7 (18.4%)
Neutropenia	5 (13.2%)	1 (2.6%)	6 (15.8%)
Lymphopenia	4 (10.5%)	1 (2.6%)	5 (13.2%)
Thrombopenia	12 (31.6%)	0	12 (31.6%)
Anemia	7 (18.4%)	1 (2.6%)	8 (21.1%)

RCCEP, reactive cutaneous capillary endothelial proliferation; ALT, alanine aminotransferase; AST, aspartate aminotransferase.